Why Focusing on Pain Killers is Imperative for Medical Device Startups: Interview with Daniel Hawkins, CEO of Shockwave Medical

Daniel Hawkins is the President and CEO of Shockwave Medical. He began his career in marketing and business development roles for Advanced Cardiovascular Systems, otherwise known as ACS, which is now part of Abbott Vascular. Following ACS, he held senior roles in general management, marketing, and business development with a number of private and public companies.

Daniel started the marketing department at Intuitive Surgical where he guided product feature development for the da Vinci Surgical Robot and developed key foundational marketing strategies for the company. He has also held senior leadership and/or founder roles with Endologix and Calibra Medical, which is now part of J&J. Daniel has an MBA from Stanford, a BS in economics from Wharton, and is a named inventor on over 100 patents and applications.

Interview Highlights with Daniel Hawkins

  • How his early upbringing gave rise to his entrepreneurial spirit.
  • Why focusing on pain killers is imperative for medtech startups.
  • Daniel’s early experiences at Intuitive Surgical and some of the most important lessons he learned commercializing the first surgical robot.
  • A question every medtech entrepreneur should ask themselves, “Does your product have natural pull?”
  • The importance of removing complexity and constraints when making key decisions.
  • How Daniel and his team came up with a concept for applying Lithotripsy to arterial plaque.
  • Daniel’s approach to raising money for Shockwave and how he was able to convince early investors during a tumultuous economic time.
  • Daniel’s favorite business book, the CEO he most admires, and what he’d tell his 30-year-old self.

Listen to the Interview with Daniel Hawkins

Read the Interview with Daniel Hawkins

Download a copy of the interview transcript right here.

You May Like These Articles

  • Recent
  • Featured
  • Related

Why Your Product Should Generate Revenue Versus Reduce Costs: Interview with Cognetivity CEO Sina Habibi

Cognetivity Neurosciences Co-founder and CEO Sina Habibi discusses the importance of collaborating with regulators and end users, why he primarily focuses on the value of revenue generation versus cost savings, and the benefits of teaming up with an expert fundraiser.

Demonstrating Value with Robust Clinical Trial Data: Interview with Miracor Medical CEO Olivier Delporte

Miracor Medical CEO Olivier Delporte explains why he advocates for randomized clinical trials, how remote monitoring tools can make clinical trial programs more efficient, and why startups should increase their fundraising goals.

How to Convince Investors, Payers, and Patients Your Device is Worth the Cost: Interview with Bone Health Technologies CEO Laura Yecies

Bone Health Technologies CEO Laura Yecies shares why you should look for investors who are passionate about your mission, how FDA clearance can boost consumer confidence in your technology, and why patients should be at the center of everything you do.

The Importance of Going All In On Your Medtech Business: Interview with SynerFuse Co-Founders Justin Zenanko and Greg Molnar

SynerFuse Co-Founders Justin Zenanko and Greg Molnar share their experience launching an innovative therapy to address chronic back pain, how they are navigating challenging regulatory waters, and why they chose to invest heavily in their own venture.

Conquering the Coverage and Reimbursement Landscape: Interview with Bruce Shook, President of Intact Vascular

In this interview, Bruce Shook discusses medical device insurance coverage and reimbursement, as well as advice for other healthcare entrepreneurs that need to raise money.

Why Curiosity and Persistence are Crucial Characteristics for Medtech Entrepreneurs: Interview with the Legendary Dr. John Simpson, Executive Chairman of Avinger

In this interview, the legendary Dr. John Simpson shares what drew him to the field of cardiology, his approach to building a medtech team, and why knowing your strengths and limitations is key to making a difference in the lives of others.

After Selling 2 Cardiovascular Companies for Over $1 Billion, Duke Rohlen is Now Hoping to do the Same with Spirox and Advanced Cardiac Therapeutics

In this interview with Duke Rohen, he discusses how he successfully led two early-stage medtech companies at the same time and the major lessons he learned raising money for 4 different medical device companies.

Having a Heart Attack? There’s an App for That! The Incredible Story of How Dr. David Albert Brought the ECG iPhone App to Market

In this interview with Dr. David Albert, we learn about his incredible journey in bringing the first iPhone ECG app to market with AliveCor.

Why Your Product Should Generate Revenue Versus Reduce Costs: Interview with Cognetivity CEO Sina Habibi

Cognetivity Neurosciences Co-founder and CEO Sina Habibi discusses the importance of collaborating with regulators and end users, why he primarily focuses on the value of revenue generation versus cost savings, and the benefits of teaming up with an expert fundraiser.

Demonstrating Value with Robust Clinical Trial Data: Interview with Miracor Medical CEO Olivier Delporte

Miracor Medical CEO Olivier Delporte explains why he advocates for randomized clinical trials, how remote monitoring tools can make clinical trial programs more efficient, and why startups should increase their fundraising goals.

How to Convince Investors, Payers, and Patients Your Device is Worth the Cost: Interview with Bone Health Technologies CEO Laura Yecies

Bone Health Technologies CEO Laura Yecies shares why you should look for investors who are passionate about your mission, how FDA clearance can boost consumer confidence in your technology, and why patients should be at the center of everything you do.

The Importance of Going All In On Your Medtech Business: Interview with SynerFuse Co-Founders Justin Zenanko and Greg Molnar

SynerFuse Co-Founders Justin Zenanko and Greg Molnar share their experience launching an innovative therapy to address chronic back pain, how they are navigating challenging regulatory waters, and why they chose to invest heavily in their own venture.